In recent developments, health officials in Europe have launched an investigation into the popular weight loss drug Ozempic, ...

Ozempic is under clinical development by Novo Nordisk and currently in Phase III for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD).

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...

Denmark's drug regulator asks EMA to investigate potential link between Novo Nordisk's diabetes drug Ozempic and rare eye ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

New studies link diabetes drug Ozempic to increased risk of NAION, a rare eye condition causing vision loss. Danish Medicines ...

Oh, oh, oh, with Khloe Kardashian now chiming in, it seems everyone in Hollywood—including Jessica Simpson, Sophie Turner, ...

Mounjaro and Ozempic are both GLP-1 receptors that can be used to help people with diabetes. The treatments are also ...